Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems, enhancing its Peripheral Vascular portfolio with next-generation intravascular lithotripsy (IVL) technology. This acquisition aims to address unmet clinical needs in treating calcified peripheral arterial disease. The IVL platform utilizes pulsed CO₂-generated pressure waves to optimize treatment efficiency. The transaction is subject to customary closing conditions, and both companies will continue to operate separately until the deal is finalized. Stryker's CEO, Kevin Lobo, emphasized the importance of this acquisition in expanding treatment options for patients.